OR56B1

Across TCGA pan-cancer cohorts, OR56B1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated OR56B1 data layer compared with 16 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher OR56B1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR56B1 expression acts as an unfavorable survival marker.

SKCM, SARC, and UCEC are the cancer types where OR56B1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	II,III,IV	0.266	0.603	.006	12	view →
SARC	DFS	Median	All	0.130	0.613	.003	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	OS	Median	All	0.246	0.617	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

OR56B1–SKCM (DFS)

Open the SKCM breakdown →